Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Apply
NK Cells
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step